Spectrum Pharmaceuticals (SPPI) Tuesday provided a full-year revenue outlook which is currently below analysts' expectations. The current guidance reflects an anticipated change in ordering patterns of FUSILEV due to the recent stabilization of the folate analog market.
Full-year revenues are currently forecast in a range of $160 million to $180 million. Analysts, based on consensus, currently expect full-year revenues of $297.33 million.
Full-year FUSILEV sales is expected to range between $80 million and $90 million, with first-quarter sales in the order of $10 million to $15 million.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.